{
  "docId": "019de075-cd17-7685-9273-fb1c731af40f",
  "docSlug": "16b2d7592f4634ac7cd717a996934f07",
  "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides",
  "authorId": "theravance-biopharma",
  "authorName": "Theravance Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 35,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide outlines a clinical trial methodology using a timeline-based study design.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/12",
  "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f",
  "deckJsonHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f.json",
  "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Study timeline showing Run-in, Randomization, 12-week treatment period, and Results.",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "83124bed-2756-4b09-9e4c-6ecef686c609",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "Phase 4, Randomized, Double-Blind, Parallel-Group Study in Adults With Severe-to-Very-Severe COPD and Suboptimal Inspiratory Flow Rate. *Dry powder inhaler (Spiriva® HandiHaler®). COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; PIFR, peak inspiratory flow rate.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6294ca20-f2c1-45e2-a77e-8bbf4dd37a84",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.05,
        "y": 0.6
      },
      "kind": "list",
      "text": "Sample size: N = Up to 488 GOLD 3 and 4 patients; Top-line data in Q4'23",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a843f48f-ec62-41d6-9912-3caa670d6d15",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.5,
        "x": 0.45,
        "y": 0.6
      },
      "kind": "list",
      "text": "Endpoints: Primary: Change from baseline in trough FEV1 (Day 85); Key secondary: Trough overall treatment effect on FEV1",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca5b123b-7500-4717-a040-1e45dadc6462",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "YUPELRI®: Phase 4 Randomized, Double-Blind, Parallel-Group Study (PIFR-2)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa1933ec-032b-4f0d-90bc-3b9cac428a4e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "b6bde032-bbf1-4dac-9606-e0bda6dbd5f8",
      "evidence": "The slide contains a list of bullet points.",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "dad151de-52c8-4299-b4c0-8cdfd7c702a2",
      "evidence": "The timeline visualization represents the study phases and duration.",
      "confidence": 0.7
    }
  ],
  "arcBeats": [
    {
      "to": 18,
      "from": 11,
      "beatId": "ae4646ce-73d8-418d-9390-888b787632a7",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The document presents the company's progress and potential for YUPELRI and Ampreloxetine",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 17,
      "from": 10,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "f11bf40d-c1c5-42f1-a514-3da6d8f2856f",
      "evidence": "The document highlights the significant unmet need for MSA patients",
      "position": 1,
      "objective": "Emphasizing the cost of inaction for MSA patients",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}